Investor Presentation

Dermatomyositis Program Overview 27 X Second targeted rare autoimmune disease in Phase 3 study ‒‒‒‒I Phase 2 results funded by NIH grant FDA Orphan Drug Designation in U.S. ‒‒‒‒‒ Ongoing open-label extension: 52 weeks+ EUROPEAN MEDICINES AGENCY SCIENCE MEDICINES HEALTH II Lenabasum Ongoing Phase 3 DETERMINE study Orphan Designation from E.U.

View entire presentation